NCT02335164View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 1, 2017

Study Completion Date

May 1, 2019

Conditions
Influenza
Interventions
BIOLOGICAL

recombinant influenza hemagglutinin

recombinant influenza hemagglutinin

BIOLOGICAL

Advax1

Delta inulin adjuvant formulation 1

BIOLOGICAL

Advax2

Delta inulin adjuvant formulation 2

Trial Locations (1)

5042

Flinders University, Adelaide

All Listed Sponsors
collaborator

Flinders University

OTHER

collaborator

Australian Respiratory and Sleep Medicine Institute

OTHER

lead

Vaxine Pty Ltd

INDUSTRY

NCT02335164 - A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults | Biotech Hunter | Biotech Hunter